CD274 and non-small cell lung carcinoma: In phase 2 trial NCT03563716, tiragolumab (α-TIGIT) plus atezolizumab significantly improved both response rates (OR: 2.57, 95%CI: 1.07–6.14) and PFS (HR: 0.57; 95%CI 0.37–0.90) in PD-L1 positive NSCLC patients, compared with the control group receiving placebo and atezolizumab (152).